Results 31 to 40 of about 5,752,243 (395)
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Antibodies, 2017 2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho +6 more
doaj +1 more source
Chromosome 1q21 abnormalities in multiple myeloma
Blood Cancer Journal, 2021 Gain of chromosome 1q (+1q) is one of the most common recurrent cytogenetic abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly diagnosed cases.
T. Schmidt, R. Fonseca, S. Usmani
semanticscholar +1 more source
The RAG Model: a new paradigm for genetic risk stratification in multiple myeloma [PDF]
, 2014 Molecular studies have shown that multiple myeloma is a highly genetically heterogonous disease which may manifest itself as any number of diverse subtypes each with variable clinicopathological features and outcomes.
Chevassut, Timothy J +2 more
core +3 more sources
Haematologica, 2018 Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe.
Jennifer Mosebach +8 more
doaj +1 more source
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, 2019 BACKGROUND Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T‐cell therapy that targets B‐cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS In this phase 1 study involving patients with
N. Raje +22 more
semanticscholar +1 more source
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells [PDF]
, 2017 Natural Killer cells are innate lymphocytes involved in tumor immunosurveillance. They express activating receptors able to recognize self-molecules poorly expressed on healthy cells but up-regulated upon stress conditions, including transformation ...
Cippitelli, M +13 more
core +1 more source
Hematology, 2002 AbstractThis update provides new insights into the biology, diagnosis, prognosis, and treatment of multiple myeloma (MM) and its complications.In Section I, Drs. John Shaughnessy, Jr., and Bart Barlogie first correlate global gene microarray expression profiling of patient MM samples with normal plasma cells to provide the basis for a developmental ...
Kenneth C, Anderson +4 more
openaire +2 more sources
Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools
Diagnostics, 2020 Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states.
Jihane Khalife +2 more
doaj +1 more source
Role of osteocytes in multiple myeloma bone disease [PDF]
, 2014 PURPOSE OF REVIEW: Despite the increased knowledge of osteocyte biology, the contribution of this most abundant bone cell to the development and progression of multiple myeloma in bone is practically unexplored.
Bellido, Teresita +2 more
core +1 more source
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
Blood Advances, 2020 Key Points We report the first case of coronavirus disease 2019 (COVID-19) in a multiple myeloma patient successfully treated with tocilizumab. Although tocilizumab was effective in the treatment of COVID-19 in this case, randomized controlled trials are
Xuhan Zhang +7 more
semanticscholar +1 more source